Speaker: John Charpentier, PhD, Business Development Manager, Biocytogen Boston

• Translational challenges in immunotherapy impede the successful transition of many therapeutic candidates to the clinic
• Biocytogen’s humanized mice are rigorously designed and validated in the following ways to improve translation of CD3-targeting candidates: Expression (mRNA & flow cytometry), Immune cell frequency & maturation profiling and functional validation using reference antibodies whenever available
• Humanized mice allow for robust preclinical modeling/testing for novel CD3-targeting therapies, including: Mono-and bispecific antibody candidates, Novel combination therapies, Preliminary toxicity assessments